Ascendis Pharma A/S (ASND)
275.39
+8.32
(+3.12%)
USD |
NASDAQ |
Nov 13, 16:00
275.04
-0.35
(-0.13%)
After-Hours: 19:59
Ascendis Pharma Price to Book Value : 10.60 for Nov. 13, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 10.60 |
| November 12, 2026 | 10.28 |
| November 11, 2026 | 9.979 |
| November 10, 2026 | 9.876 |
| November 09, 2026 | 10.00 |
| November 06, 2026 | 9.885 |
| November 05, 2026 | 9.755 |
| November 04, 2026 | 9.927 |
| November 03, 2026 | 9.629 |
| November 02, 2026 | 9.583 |
| October 30, 2026 | 9.671 |
| October 29, 2026 | 9.738 |
| October 28, 2026 | 9.605 |
| October 27, 2026 | 9.462 |
| October 26, 2026 | 9.435 |
| October 23, 2026 | 9.367 |
| October 22, 2026 | 9.352 |
| October 21, 2026 | 9.195 |
| October 20, 2026 | 9.019 |
| October 19, 2026 | 8.850 |
| October 16, 2026 | 8.670 |
| October 15, 2026 | 8.722 |
| October 14, 2026 | 8.737 |
| October 13, 2026 | 8.591 |
| October 12, 2026 | 8.737 |
| Date | Value |
|---|---|
| October 09, 2026 | 8.823 |
| October 08, 2026 | 8.571 |
| October 07, 2026 | 8.791 |
| October 06, 2026 | 8.700 |
| October 05, 2026 | 8.776 |
| October 02, 2026 | 8.770 |
| October 01, 2026 | 8.749 |
| September 30, 2026 | 8.769 |
| September 29, 2026 | 9.12 |
| September 28, 2026 | 9.199 |
| September 25, 2026 | 9.021 |
| September 24, 2026 | 9.225 |
| September 23, 2026 | 8.922 |
| September 22, 2026 | 9.500 |
| September 21, 2026 | 9.501 |
| September 18, 2026 | 9.466 |
| September 17, 2026 | 9.559 |
| September 16, 2026 | 9.904 |
| September 15, 2026 | 9.588 |
| September 14, 2026 | 10.59 |
| September 11, 2026 | 10.54 |
| September 10, 2026 | 10.45 |
| September 09, 2026 | 10.43 |
| September 08, 2026 | 10.80 |
| September 04, 2026 | 10.82 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| BioMarin Pharmaceutical, Inc. | 1.772 |
| Novo Nordisk A/S | 5.561 |
| Genmab A/S | 4.988 |
| Zealand Pharma A/S | 0.9113 |
| Evaxion AS | 2.398 |
Price to Book Value Related Metrics
| PE Ratio | 17.73 |
| PS Ratio | 12.96 |
| Price to Free Cash Flow | 30.27 |
| Price | 275.39 |
| Earnings Yield | 5.64% |
| Market Cap | 18.09B |
| Operating PE Ratio | 70.59 |
| Normalized PE Ratio | 17.73 |